Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Letermovir Prophylaxis for CMV in Patients With Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation: a Proof of Concept Multicenter Study

NCT05969743 is registered in ClinicalTrials.gov with Rabin Medical Center as lead sponsor.

NCT NCT05969743
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05969743 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Letermovir Prophylaxis for CMV in Patients With Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation: a Proof of Concept Multicenter Study
Lead sponsor
Rabin Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2023
Completion date
July 31, 2025
Enrollment
42 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cmv, graft-versus-host-disease